eighth bio spectrum june 10

8/6/2019 Eighth Bio Spectrum June 10

1/15


2/15

A CybrMdia Pblicatio | biospctrmidia.com | June 2010 | BIOSPECTRUM | 19

Biotech Directory

2009-10

BioSpectrumconductedthissurveyjointlywiththeAssociationofBiotechnologyLedEnterprises(ABLE).BioSpectrumandABLEhavejointlybeendoingthis

exercisesince2003.Adetailedquestionnaire(surveyform)wassenttoover150companiestocapturetheneededinformationfortheanalysis.ThiswasdoneduringApril-May2010.Companiessharedinformationwithustotheextentitwaspossiblebythemabouttheircompaniesandtheindustry.

Therevenuesconsideredfortheanalysisarebiotechproductssalesandservicefigures.Inseveralcases,whererevenuefigureswerenotavailableestimateswerearrivedtalkingtoindustryexperts.Thesearedenoted(*)asBioSpectrumestimates.

ThisyearinthelistofTop20biotechcompanies,serv-icescompaniesinthedrugdiscoveryspacehavebeentakenintoaccount,whilediagnosticscompanieshavenotbeenconsidered.Anoveralllistingofcompanies(Page110&112)byrevenuehasbeendoneforyourreferenceincludingdiagnosticcompanies.

Biotechsuppliersrevenuesarenotconsideredaspartofthebiotechdefinition.

BioPharmaincludedproductsmadebyfermentation/animalcellculture(notanimalextracts)andplantcellculture(notplantextracts).

TheBioAgrisegmentanalysishasincludedonlytheGMseedsandmolecularmarkersandrelatedproducts.So,thehybridseedsbusinessisnotapartoftheagri-busi-

nesssalesvalues. Foralltherankingpurposes,wehavetakenthebiotech

businessonlyintoconsideration.WhereverTURNOVERismentioneditmeans,salesturnoverfrombiotech.Therefore,turnoverwherevermentionedisnotneces-sarilythetotalsalesturnoverofthecompany.

SURVEY & RANKING METHODOLOGY

IndustryOverviewIndustryOverview

BioSpectrumABLE Biotech Industry Survey 2010


3/15

20 | BIOSPECTRUM | June 2010 | biospctrmidia.com | A CybrMdia Pblicatio

Biotech Directory

2002-03

1790

75235

110 135

80238

130275

2752

3570

100320

330425

4708

120375

598

720

5973

145

395

926

11026899

190

410

1201

1572

7883

220

478

1494

2062

8829

231

564

1936

2639

2003-04 2004-05 2005-06 2006-07 2007-08 2008-09 2009-10

INDIA BIOTECH INDUSTRY 2002-10

FY

BioInformatics

BioIndustrial

BioAgri

BioServices

BioPharma

TotalRevenue

Total-2345

Total-3475

Total-12137

Total-14199.17

Total-10272

Total-8541

Total-6521

Total-4745

0

2500

5000

7500

10000

12500

15000

India biotech

$3 bn

Size

Registers Rs 14,199 crGrows17%recovers

Industry Overview


*AllfiguresinRs.Croreunlessindicatedotherwise


4/15


Biotech Directory

Biotech Industry Exports vs Domestic 2009-10

Segment Exports Domestic Total % shareExports

% shareDomestic

Biopharma 4767.66 4061.34 8829 54 46

BioServices 2507.05 131.95 2639 95 5

BioAgri 58.08 1877.92 1936 3 97

BioIndustrial 124.08 439.92 564 22 78

BioInformatics 73.92 157.08 231 32 68

Total 7530.79 6668.21 14199 53.04 46.96

Biotech Industry Exports vs Domestic 2008-09

Segment Exports Domestic Total % shareExports

% shareDomestic

Biopharma 4868 3015 7883 62 38

BioServices 1964 98 2062 95 5

BioAgri 61 1433 1494 4 96

BioIndustrial 89 389 478 11 89

BioInformatics 50 170 220 23 77

Total 7152 4985 12137 59 41

BioAgri

grows at37%

28%BioServicesfollows at

In dollar terms, the industry

crossed$3billioninFY2009-10

growing23% overa flatgrowth

ofFY2008-09.

Exportsaccountedfor53%share

in the overall revenue and reg-istered a growth of5%overFY

2008-09.

Domestic business claimed 47%

shareintheoverallrevenueand

registeredagrowthof34%over

FY2008-09.

Industry Overview




5/15


Biotech Directory

61.71 18.78

13.93

3.95

1.63

Biotech Industry Segment Revenue % Share

% Share 2010

64.9516.99

12.31

3.941.81

% Share 2009

BioPharma

BioServices

BioAgri

BioIndustrial

BioInformatics

40

35

30

25

20

15

10

0

Revenueshare%changeover2007-2008

Revenueshare%changeover2008-2009

Biotech Industry SegmentRevenue % Change

Biopharma BioServicesBioAgriBioIndustrialBioInformatics

Segment 2007-08 2008-09 2009-10 %ChangeOver2007-08

%ChangeOver2008-09

Biopharma 6899 7883 8829 14 12

BioServices 1572 2062 2639 31 28

BioAgri 1201 1413 1936 23 37

BioIndustrial 410 478 564 16 18

BioInformatics 190 220 231 16 5

Total 10272 12137 14199 100 100

Biocon back

to No. 1 slot

Company Highlights

Industry Overview


Total revenue Rs 14,199 Crore Total revenue Rs 12,137 Crore


Top20companiescontributed52%ofthetotalrevenue.

Thesecompaniesgrewatanaveragegrowthrateofover22%

whiletheindustrygrowthratestoodat17%inFY2009-10.

SerumInstituteofIndiaslippedtoNo.2onaccountoflossof

somekeycontracts.

ShanthaBiotechistheonlyTop20revenuecompanytohaveshowcasedagrowthover30%percent.

TotalrevenuesofTop20homegrowncompanieshavegrown

by25%overFY2008-09.

Fastestgrowing20companiescontributed20%oftheoverall

industryrevenueofRs14199.17crore.Thesehavegrownat

anaveragerateofover150%.

Thepackoffastestgrowingcompaniesintheregionisledby

CROs,whicharegrowingfromaverysmallbaseoflessthan

Rs30crore.

The fastest growing 20 companies in the region are all

belowRs150crorewiththeexceptionofShanthaBiotechatRs334.23crore.


6/15


Biotech Directory

RevenueRank2010

Company2009-10(Revenue

inRsCr)2008-09(Revenue

inRsCr)2007-08(Revenue

inRsCr)%Change

Over2007-08%ChangeOver

2008-09

1 Biocon 1180 912.34 876.93 4.04 29.34

2 Serum Institute of India* 850 1114.00 987.00 12.87 -23.70

3 Panacea Biotec 703.19 597.14 681.16 -12.33 17.76

4 Nuziveedu Seeds 476.86 449.58 291.88 54.03 6.07

5 Reliance Life Sciences* 450

6 Quintiles* 375

7 Rasi Seeds 358.78 375.59 293.68 27.89 -4.48

8 NovoNordisk* 342 330.00 260.00 26.92 3.64

9 Shantha Biotech 334.23 247.00 150.00 64.67 35.32

10 Mahyco 312 211.12 135.86 55.40 47.78

11 Indian Immunologicals 272.87 231.46 172.70 34.02 17.89

12 Bharat Biotech 271.66 241.05 83.44 188.89 12.70

13 Novozymes South Asia* 268 250.00 225.00 11.11 7.2014 Monsanto* 255 345.00 -26.09

15 Syngene International 252 224.60 175.50 27.98 12.20

16 Jubilant Organosys 249.3 242.00 159.00 52.20 3.02

17 Eli Lilly 187 164.00 149.00 10.07 13.85

18 Bharat Serums 175 140.00 140.00 0.00 25.00

19 Haffkine Biopharma 168.98 88.61 -100.00

20 Siro Clinpharm 150 280.00 -46.43

Top 20 Biotech Companies by Revenue (2009-10)

Industry Overview


Revenue

Rank2010Company

2009-10(Revenue

inRsCr)

2008-09(Revenue

inRsCr)

2007-08(Revenue

inRsCr)

%Change

Over2007-08

%ChangeOver

2008-091 Stempeutics 17.19 1.06 1.42 -25.35 1521.70

2LambdaTherapeuticResearch*

145 30.00 383.33

3MaxNeemanInternational

40 15.00 10.00 50.00 166.67

4 ConcordBiotech 111.7 52.13 53.13 -1.88 114.27

5 KrishidhanSeeds 133.23 63.25 47.70 32.60 110.64

6 AventisPharma 68.34 36.00 105.00 -65.71 89.83

7 Maps(India)* 45 25.00 80.00

8 NathSeeds 85 48.50 62.00 -21.77 75.26

9 AnthemBiosciences 53 32.34 63.88

10 SuvenLifeSciences 33.5 21.03 27.70 -24.08 59.30

11 CadilaHealthcare 147.48 93.70 77.04 21.63 57.40

12 DrReddysLaboratories 62.5 40.00 34.00 17.65 56.25

13 Mahyco* 312 211.12 135.86 55.40 47.78

14 GlaxoSmithKline 123.34 83.48 80.65 3.51 47.75

15 Wyeth* 53 37.00 43.24

16 AdvancedEnzymes 121 88.60 69.30 27.85 36.57

17 AnkurSeeds 109.5 80.35 55.73 44.18 36.28

18 ShanthaBiotech 334.23 247.00 150.00 64.67 35.32

19 JKAgrigenetics* 35 26.00 46.00 -43.48 34.6220 ABLBiotechnologies 14.81 11.31 20.03 -43.53 30.95

Top 20 Biotech Companies by Growth (2009-10)

AllfiguresinRs.Croreunlessindicatedotherwise*BioSpectrumestimates


7/15


Biotech Directory

Top 20 Homegrown Biotech Companies by Revenue (2009-10)Revenue

Rank2010Company

2009-10(RevenueinRsCr)

2008-09(Rev-enueinRsCr)

2007-08(Rev-enueinRsCr)

%ChangeOver2007-08

%ChangeOver2008-09

1 Biocon 1180 912.34 876.93 4.04 29.34

2SerumInstituteofIndia*

850 1114.00 987.00 12.87 -23.70

3 PanaceaBiotec 703.19 597.14 681.16 -12.33 17.76

4 NuziveeduSeeds 476.86 449.58 291.88 54.03 6.07

5 RelianceLifeSciences* 450

6 RasiSeeds 358.78 375.59 293.68 27.89 -4.48

7 ShanthaBiotech 334.23 247.00 150.00 64.67 35.32

8 IndianImmunologicals 272.87 231.46 172.70 34.02 17.89

9 BharatBiotech 271.66 241.05 83.44 188.89 12.70

10 SyngeneInternational 252 224.60 175.50 27.98 12.2011 JubilantOrganosys 249.3 242.00 159.00 52.20 3.02

12 BharatSerums 175 140.00 140.00 0.00 25.00

13 HaffkineBiopharma 168.98 88.61 -100.00

14 SiroClinpharm 150 280.00 -46.43

15 CadilaHealthcare 147.48 93.70 77.04 21.63 57.40

16LambdaTherapeuticResearch*

145 30.00 383.33

17 KrishidhanSeeds 133.23 63.25 47.70 32.60 110.64

18 IntervetIndia* 121.6

19 AdvancedEnzymes 121 88.60 69.30 27.85 36.5720 IntasBiopharma 115 89.27 47.29 88.77 28.82

WesternclustercontinuestodominateIndiasbiotechindustrywith46%

shareintheoverallrevenuesofRs14,199crore.The137companiesinthe

regionbetweenthemselvesclockedRs6,631croreinFY2009-10increas-

ingtheregionsshareintheoverallrevenuesby3%overFY2008-09,thus

gainingaleadof6%overSouth,itsclosecompetitorforthetopslot.

TheIndianBioPharmamarketcomprisingprimarilyofvaccines,thera-

peuticdrugs,insulin,animalbiologicals,statinsanddiagnosticsin2009-2010,continued tograbthe largest shareof the totalbiotech industry

revenuesofoverRs14,199crore.ItcontributedRs8829crore,accounting

for62%revenueshare.

IntermsofPEfundinginlifesciences,in2009-10anestimated$200mil-

lionwas investedin the Indiabiotechindustrywith40%ofthisbeing

pumpedintotheBioPharmasegment.WithinBioPharmavaccines,di-

agnosticsandmedicaldeviceshavebeenthelucrativesectorsformostof

theIndianPEinvestors.InvestorsarealsobullishaboutmAbsspace.

ThegovernmentofIndiathroughDepartmentofBiotechnology(DBT)al-

locatedRs902croreforvariousprojectsin2009-10.Thisallocationfor

2010-11isRs1,200crore.Thecollaborationsandpublic-privatepartner-

shipsinthebiotechindustryareontherise.TheinitiativesfromDBT

SmallBusinessInnovationResearch Initiative (SBIRI),andtheBill&

MelindaGatesFoundation are some of the examplesof collaborations

betweengovernmentandindustry.DBThasalsotiedupwithUK-based

Wellcome Trust to enhance cutting-edge biomedical research in India.

Thetrusthasallocated30millionpoundsforaperiodoffiveyearstofund

R&DresearchinIndia.

ItwastheYearofRecovery

fortheindustrymarkedby

consolidation,collaborations

andaspateofdealsbetween

pharmaandbiotechs.The

secondhalfof2009sawmostcompanies,primarily

biopharmacompanies,

postinghealthiertopline

andmargins.TheShantha

Biotech-SanofiPasteurdeal

in2009becameadefining

pointintheindustrywith

Shanthaselling-outateight

timesitsvaluationofRs

3,475crore($770million).

ThetrendofMNCsscouting

forandacquiringdomestic

playerswithastrongfoothold

inthemarketpickedup

steamafterthis.

Industry Overview

AllfiguresinRs.Croreunlessindicatedotherwise


*BioSpectrumestimates


8/15


Biotech Directory

Western cluster continues to

dominate Indias biotech

industry with 46 percent

share in the overall revenues of Rs

14,199 crore. The 137 companies

in the region between themselves

clocked Rs 6,631 crore in FY 2009-10

increasing the regions share in the

overall revenues by 3 percent over

FY 2008-09, thus gaining a lead of 6

percent over South, its close competi-

tor for the top slot.

Not just that, this year, Mumbai

outpaced Bangalore to become Indias

Top Biotech City with a small margin

of about Rs 200 crore in terms of rev-

enue. Besides, Gujarats share in the

total revenue has grown by almost 50

percent as compared to its revenues

of Rs 755 crore in 2008-09. In Ma-

harashtra , Punes contribution wentdown as the leading company of the

region Serum Institute of India suf-

fered contract set backs.

So, has South regions position vis-

a-via West worsened since last year?

Not really. Given the policy and in-

frastructure push the situation next

year could even see a dramatic shift.

South continues to remain Indias

largest Biotech cluster in terms of

the number of companies. In 2009-

10, it added another 9 companies

highest in the country. The region

has 172 biotech companies (West has

137 companies), which churned out

Rs 5537.68 crore in revenues in FY

2009-10 making up 39 percent of the

overall revenues.

In the South region, Karnataka

state government has proposed to set

up five new biotech parks and has in-

vested Rs 1,100 crore towards new in-

itiatives in 2009-10. Another biotechhub Andhra Pradesh is also setting

up a MedTech Valley, a world-class

Top Companies in NorthCompany 2009-2010 (Revenue in

Rs Cr)% Share in

Region% Share of Total

Biotech

Panacea Biotec 703.19 34.63 4.95

Jubilant Organosys 249.30 12.28 1.76

Eli Lilly 186.72 9.20 1.32

Top 3 North 1139.21 56.11 8.02

Total North 2030.48 14.30

Top Companies in SouthCompany 2009-2010 (Revenue

in Rs Cr)% Share in

Region% Share of Total

Biotech

Biocon 1180 21.31 8.31

Nuziveedu Seeds 476.86 8.61 3.36

Rasi Seeds 358.78 6.48 2.53

NovoNordisk* 342 6.18 2.41

Shantha Biotech 334.23 6.04 2.35

Indian Immunologicals 272.87 4.93 1.92

Bharat Biotech 271.66 4.91 1.91

Novozymes South Asia 268 4.84 1.89Syngene International 252 4.55 1.77

Ecron Acunova 97 1.75 0.68

Top 10 South 3853.40 69.59 27.14

Total South 5537.68 39.00

Top Companies in WestCompany 2009-2010 (Revenue in

Rs Cr)% Share in

Region% Share of

Total Biotech

Serum Institute of India* 850 12.82 5.99

Reliance Life Sciences* 450 6.79 3.17

Quintiles* 375 5.66 2.64

Mahyco 312 4.71 2.20

Monsanto* 255 3.85 1.8

Bharat Serums 175 2.64 1.23

Haffkine Biopharma 168.98 2.55 1.19

Siro Clinpharm 150 2.26 1.06

Cadila Healthcare 147.48 2.22 1.04

Lambda Therapeutic Research* 145 2.19 1.02

Ajeet Seeds* 103 1.55 0.73

Top 10 West 2883.46 43.48 20.31

Total West 6631.01 46.70

BioCluster


West retains No position1The region has improved its lead over South by 6%

Mumbai outpaces Bangalore, becomes Indias Top Biotech City

All figures in Rs. Crore unless indicated otherwise*BioSpectrum estimates


9/15


Biotech Directory

0

2500

5000

7500

10000

12500

15000

2002-03 2004-05 2005-06

Top Biotech Clusters & Cities (2009-10)cluster for manufacturing medical

devices and equipment near Genome

Valley at Shameerpet in Hyderabad.

The state government will provide

1,200 acres of land for the project.

The project will be executed via apublic-private partnership model.

Kerala has also taken steps to jump

on the biotech bandwagon. Kerala

State Industrial Development Corp

(KSIDC) has announced that it will

set up a state-of-the-art life science

park at Thiruvananthapuram at an

estimated cost of Rs 300 crore. The

project that will come up in 260 acres

at Thonnakkal, would be developed

under public-private partnership

model. The park will house an incu-

bation center, a technology develop-

ment center, biotechnology compa-

2003-04

BioCluster


West

South

North

Total

Top 10 companies in the West have 43%

share in the region.

Serum Institute of India

(Rs 850 crore), the regions No 1 company

makes up for about 13% of the regions

revenue and contributes 6% to the overall

industry revenue.

Biotech Revenue Cluster Trend (2002-10)


10/15


Biotech Directory

2006-07 2007-08 2008-09

nies, drug discovery companies, pure

play firms and also contract research

outsourcing units.

Looking ahead, year 2010-15 will see

some shifts, specializations and emer-

gence of clear patterns. During thisperiod many of the mega initiatives

are likely to take off and have the po-

tential to be a leap of sorts that can

build a virtuous cycle for the region.

NCR at No 4

The Northern biocluster National

Capital Region (NCR) has the Top 3

companies contributing 56 percent of

the revenues and about 15 percent

of the overall industry revenue. This

cluster is better known for its re-

search institutes and of course, gov-

ernment bodies.

More recently, the development

of 200 acre Health Biotech Science

Cluster (HBSC) at Faridabad is un-

derway. A multidisciplinary approach

to education and research, this Bio-

tech cluster would comprise Transla-tional Health Science & Technology

Institute (THSTI), Regional Center

for Biotechnology (RCB) Center for

Vaccinology, Molecular Medicine

Center, Center for Diagnostics, Bio-

tech Park,), Center for Health Sci-

ence Technology, Center for Platform

Technologies, UNESCO Center, Incu-

bator and a Center for Animal Model

for Clinical Advances. As a first step,

a temporary THSTI lab was recently

inaugurated at Gurgaon. This would

be shifted to the main site at Farida-

bad in two-three years after the in-

frastructure is ready.

Besides, there is the biotech park

at Lucknow offering a very good plat-

form for the small and medium bio-

tech companies to do research, col-

laborate and expand their business.The Biotech Parks at three locations

Sitapura-Jaipur and Chopanki,

Bhiwadi (Alwar), and Borandi, Ra-

jasthan have been initiated by Rajas-

than State industrial Development

& Investment Corporation (RIICO).

Then, there is the proposed bioclus-

ter at Mohali (Punjab), upcoming

biotech park at Chandigarh (Pun-

jab) and another one at Nalagarh

in Himachal Pradesh all this is

expected to provide the much needed

boost to the biotech companies in the

North region.

BioCluster


West is also base for top bioagri companies such as

Monsanto, Mahyco and Ajeet Seeds.

MNCs like GlaxoSmithKline, Roche, Aventis Pharma,

Wyeth, Quintiles are also headquartered in the region.

Four of Indias top 10 services companies (CROs) are

also based out of West, including the No 1 CRO in the

Indian industry Quintiles India (Rs 375 crore)

*All figures in Rs. Crore unless indicated otherwise

2009-10


11/15


Biotech Directory

Top 20 BioPharma Companies by Revenue (2009-10)

BioPharma to grow over

10%for next

5years

BioPharma clocks Rs 8,829 crore in revenues

It accounted for 62% of the total revenue and grewby 12% over FY 2008-09

The Top 20 BioPharma companies contributed close

to Rs 6000 crore

The Indian BioPharma market

comprising primarily of vac-

cines, therapeutic drugs, insu-

lin, animal biologicals, statins and

diagnostics in 2009-2010, continued

to grab the largest share of the total

biotech industry revenues of over Rs

14,199 crore. It contributed Rs 8,829

crore, accounting for 62 percent mar-

ket share.

Vaccines had the largest pie with

an estimated sales of Rs 2,180 crore

over last years figure of Rs 2,000

crore. The vaccine segmenthuman

as well as animal vaccinesaccount-

ed for 50-60 percent of the total BioP-

harma market. Total estimated sales

from the human vaccine business

stood at Rs 1,750 crore over the 2008-

2009 figure of Rs 1,550 crore. Domes-

tic sales of human vaccines just about

crossed Rs 1,000 crore. In FY 2008-09

this figure stood at Rs 900 crore. Ex-

port sales is estimated to have gener-

ated Rs 750 crore, as compared to Rs

650 crore in FY 2008-09. Animal Vac-

cines registered a marginal decline

Revenue

Rank 2010

Company 2009-10 (Revenue in Rs Cr) 2008-09 (Revenue in Rs Cr) % Change Over

2008-091 Biocon 1180 912.34 29.34

2 Serum Institute of India* 850 1114.00 -23.7

3 Panacea Biotec 703.19 597.14 17.76

4 Reliance Life Sciences* 450

5 NovoNordisk* 342 330.00 3.64

6 Shantha Biotech 334.23 247.00 35.32

7 Indian Immunologicals 272.87 231.46 17.89

8 Bharat Biotech 271.66 241.05 12.7

9 Eli Lilly 187 164.00 13.85

10 Bharat Serums 175 140.00 25

11 Haffkine Biopharma 168.98

12 Cadila Healthcare 147.48 93.70 57.4

13 GlaxoSmithKline 123.34 83.48 47.75

14 Intervet India 121.6

15 Intas Biopharma 115 89.27 28.82

16 Themis Medicare 112.12 97.50 14.99

17 Concord Biotech 111.7 52.13 114.27

18 Venkateshwara Hatcheries* 90

19 Aventis Pharma 68.34 36.00 89.8320 Dr Reddys Laboratories 62.5 40.00 56.25

Segment Overview


All figures in Rs. Crore unless indicated otherwise* BioSpectrum estimates


12/15


Biotech Directory

with sales of Rs 430 crore over last years figure of Rs

450 crore. In animal vaccines, poultry vaccines clocked

Rs 220 crore, cattle and sheep vaccines registered Rs 210

crore.

The vaccine market will continue to drive the growth

of the biopharma segment growing in the range of 10-13percent in the next 5 years. The factors that will drive

this include education and awareness about disease pre-

vention, increase in disposable income and participation

by government.

The market will clearly shift to combination vaccinessuch as Pentavalent vaccines. Domestic players such as

Bharat Biotech and Shantha Biotech have already re-

ceived massive orders from the Government of India for

immunization programmes in Himachal Pradesh, Kerala,

Tamil Nadu, Jammu and Kashmir and Karnataka. There

is going to be a change from largely whole-cell pertusis

-based combos to acellular-based combos in the coming

years. Newer vaccines like Pneumo conj, Meninge Conj

and HPV would drive the market growth in paediatric

and adolescent segment, while Flu will continue to be a

big driver in the adult market segment.

A noteworthy product launched during 2009-2010 was

Shanthas ShancholIndias first oral vaccine to pro-

tect against cholera. Shanchol is a bivalent inactivated-

whole-cell oral cholera vaccine developed by Shantha in

collaboration with the International Vaccine Institute

(IVI), Seoul, Korea.

Driven by a rise in chronic diseases and investments inthe healthcare infrastructure, diagnostics and thera-peutics business also had a positive impact on the industry.

The diagnostic market is estimated to be at Rs 2,000 crore

with molecular diagnostic market share at $300 million in

FY 2009-2010. This accounts for 20-22 percent share of thetotal BioPharma market. A highly competitive segment,

the market currently is growing at 15-20 percent with a

50:50 revenue share split between MNCs and homegrown

companies. Major MNC companies in the diagnostic mar-

ket include Roche, Siemens (which has acquired Bayer Di-

agnostics) and Abbott while homegrown names in the top

league include Tulip Group, Transasia Biomedicals, RFCL(Diagnova), Span Diagnostics and Trivitron. This growth

is driven from the gradual acceptance of the concept of pre-

ventive and personalized medicine. The therapeutics mar-

ket claimed 15 percent of market share in FY 2009-2010

with the cancer therapeutics sales clocking Rs 311 crore.

Companies in the segment are now moving towards nov-

el targeted therapies and supportive care products. Can-

cer therapeutics is a lucrative business for many Indian

companies because of high unmet needs, high prices of

innovator drugs, increase of awareness and affordability.

These homegrown players will play a pivotal role in re-

ducing the price points of important cancer drugs.

The market size of Oral Diabetes Drugs is estimated to

be Rs 1,550 crore and market size of Insulin (including

analogs) is approximately Rs 612 crore. The large mar-

ket size is reflective of India emerging as the diabetes

capital of the world. Between 1995 and 2005 the number

of diabetic patients doubled from 20 million to 40 mil-

lion and this is projected to grow to 70 million patients

by 2025. In Insulin (including Analog) segment, Novo

Nordisk is the market leader with over 50 percent mar-

ket share while Eli Lilly has 22 percent market share.

Analogs which currently contribute 27 percent in value(8 percent in volume) are the fastest growing segment

(with 2007-09 CAGR of 32 percent) in value. Within in-

sulin market, novel delivery devices would be the growth

drivers in the coming years.

Biogenerics segment in the near term will be a keygrowth driver for Indian players especially with theUS set to establish a biogenerics (biosimilars) pathway

by 2013. In India, Erythropoietin (EPO) clocked a sales

of Rs 10 lakh ($22,000), c-GSFRs 5 lakh ($11000), in-

terferonRs 10 lakh $22000 and streptokinase Rs 7 lakh

($16000). These products are been sold at price discounts

of upto almost 85 percent of its innovator drug thus mak-

ing them affordable to the masses. Currently, Dr Reddys

Labs, Ranbaxy, Biocon, Shantha Biotechnics and Intas

Biopharmaceuticals are actively involved in the space.

There are around 25 Indian players with over 50 prod-

ucts already being sold in the Indian market and some

being sold in the unregulated markets as well. Other

prominent companies that have started initiatives in the

field include Glenmark, Cipla and Lupin Pharma. Last

year, Cipla entered into a 50:50 joint venture (JV) with a

Chinese company for biosimilars. The JV would be called

Biomab and Cipla is likely to bring out Biomabs firstproduct later this year.

Segment Overview


The vaccine market will continue to

drive the growth of the biopharma

segment growing in the range of

10-13% in the next 5 years


13/15


Biotech Directory

BioServices segment registered

a growth of 28 percent in

2009-10 over last years total

segment revenue of Rs 2,062 crore.

The 3 percent drop in growth from a

31 percent of 2008-09 was primarily

due the currency fluctuations in FY

2009-10. Exports continue to domi-

nate this segment accounting for over

90 percent of the total revenues.

In this segment, accounting for 19

percent of overall revenue, compa-

nies such as Lambda Therapeutic

Research, MaxNeeman and Anthem

Biosciences have done exceedingly

well in FY 2009-10 with Lambda and

MaxNeeman growing well over 100

percent and Anthem Biosciences atover 60 percent. The Top 10 CROs

make up 60 percent of the total seg-

ment revenue of Rs 2,639 crore.

In the last three-to-five years, many

companies have set up contract re-

search and clinical research services

operations in India. Considering the

potential opportunity and fast clip

market growth, the number of com-

panies in this segment will continue

to grow faster than the industry aver-

age in the next two years as well.

The segment is growing on account

of the growing requirements of the

multinational companies that are

looking at India as an outsourcing

destination with high-skill, low cost

advantage. Besides, due to business

model evolutions driven by market

forces, even the domestic companies

are outsourcing various portions of

the drug discovery chain.

However, the competition in the

segment is growing to be intense im-

pacting bottomlines adversely. Thefact that all new companies are now

born global is adding to this compe-

tition. SIRO Clinpharm having pres-

ence in India, Western & Central

Eastern Europe, and US has now

entered into an alliance with Dream-

CIS Inc., a leading CRO based out of

Top 10 Services Companies by Revenue (2009-10)Rank

2010

Company 2009-10 (Revenue

in Rs Cr)

2008-09 (Revenue

in Rs Cr)

% Change

Over 2008-091 Quintiles India* 375 --- ---

2 Syngene International 252 224.60 12.2

3 Jubilant Organosys 249.3 242.00 3.02

4 Siro Clinpharm 150 280.00 -46.43

5 Lambda Therapeuticresearch*

145 30.00 383.33

6 Veeda Clinpharm 110 --- ---

7 Ecron Acunova 97

8 Vimta Labs 88.42 81.60 8.36

9 Anthem Biosciences 53 32.34 63.88

10 Max NeemanInternational

40 15.00 166.67

Seoul in South Korea. The company

has also signed an agreement with Virginia Contract Research Organi-

zation (VCRO), a Taiwan-based CRO

to offer a range of services to Taiwan

companies. And, it is not just Asia Pa-

cific market that the company is look-

ing at. SIRO is expanding operations

in the developed markets like USA

and Europe as well. It has entered an

alliance with Advanced Clinical Trial

Solutions (ACT Solutions), Fleming-

ton, NJ, USA.

Syngene International, a subsidi-

ary of Biocon Group, has partnered

with Sapient Discovery, a US-based

biotechnology company. Both the

companies intend to provide a highly

integrated platform for structure-

based drug discovery. It also signed a

pact with another US company, Endo

Pharma, to jointly discover and de-

velop novel biological drug molecules

to fight cancer.

Bangalore-based Ecron Acunovahas tied-up with a Japanese CRO

and expects this alliance to trigger

a trend and set off 40-50 clinical tri-

als between India and Japan in the

next two-to-three years. Japan is the

second biggest pharma market after

the US. This apart, the Indo-German

clinical research major with its estab-

lished presence in India and Europe

is scouting for more market share in

clinical research in these countries

and other parts of the globe.

Veeda Clinical Research, which

has completed five years of existence

in January 2010, has opened its of-

fice in South East Asia by signing

a collaborative agreement with the

Malaysian Ministry Health to open

a Phase I and Early Clinical Develop-

ment Unit in the Ampang Hospital in

Kuala Lumpur.

India services industry is, decid-

edly, set to take the collaborationgrowth highway.

CROs take the growth highway

BioServices registers 28% growth withrevenue of Rs 2,639 crore

Top 10 CROs make up 60% of the total

segment revenue

Segment Overview

All figures in Rs. Crore unless indicated otherwise


* BioSpectrum estimates


14/15


Biotech Directory

Agri biotech is the third largest

contributor to Indian biotech

industry in FY 2009-2010

with a total segment turnover of Rs

1,936 crore, accounting for almost 14

percent of the total biotech revenues.

Registering a growth of 37 percent

over last year, BioAgri emerged the

industrys fastest growing segment.

The fact that BioServices segment

dominated by exports faced minor

setbacks on account of currency fluc-

tuations helped BioAgri gain lead.

In FY 2008-09 BioServices with a

growth of 31 percent was the fastest

growing industry segment.

India is the fourth largest country

in the world with almost 8.4 million

hectares of area under Bt cotton. On

Region Production

North 600 kg per hectare

West 516 kg per hectare

Central 472 kg per hectare

South 595 kg per hectare

one side the area under Bt cotton has

been on increasing, on the other side

the prices for Bt seeds packets has

been slightly on decline. This decline

is because of governments interven-

tion and more companies launching

different technologies for producing

Bt seeds.

The number of companies sell-

ing Bt cotton seeds in India has in-

creased dramatically over the last

eight years since the first commer-

cialization in 2002. Today, there are

over 30 companies marketing Bt cot-

ton seeds in the country.

Nuziveedu Seeds is the largest sell-

er of Bt cotton seeds. The company

sold 70 lakh packets generating Rs

476.86 crore in revenues. Rasi Seeds

is the second largest contributor withRs 358.78 crore in sales. Nuziveedu

has 25 percent of the market share

while Rasi Seeds is close second with

19 percent market share. Other sig-

nificant players include Ajeet Seeds,

Ankur Seeds selling 12-20 lakh pack-

ets each in FY 2009-10.

Top 10 Agri Companies by Revenue (2009-10)

Rank2010

Company 2009-10 (Rev-enue in Rs Cr)

2008-09 (Revenuein Rs Cr)

% Change Over2008-09

1 Nuziveedu Seeds 476.86 449.58 6.07

2 Rasi Seeds 358.78 375.59 -4.48

3 Mahyco 312 211.12 47.78

4 Monsanto* 255 345.00 -26.09

5 Krishidhan Seeds 133.23 63.25 110.64

6 Ankur Seeds 109.5 80.35 36.28

7 Ajeet Seeds* 103

8 Nath Seeds 85 48.50 75.26

9 JK Agrigenetics* 35 26.00 34.6210 Bayer CropScience* 22.5

A fast clip growth for BioAgri

Segment Overview



A total of 280 lakh packets of seeds

containing 450 grams were sold in

2009, approximately 87 percent be-

ing Bollgard II and 13 percent boll-

gard I. An additional 20 lakh packets

of spurious seeds were estimated to

have been sold illegally to the farm-

ers mainly in Gujarat state. While

in most of the regions, the Bollgard

I and Bollgard II cotton seeds were

priced at Rs 650 and Rs 750 respec-

tively. In North (mainly Punjab,

Haryana and Rajasthan), the pricing

was kept at Rs 759 for Bollgard I and

Rs 925 for Bollgard II.

The Bollgard Bt cotton seeds

were sold in nine states-AndhraPradesh, Tamil Nadu, Karnataka,

Gujarat, Madhya Pradesh, Mahar-

ashtra, Haryana, Punjab, and Ra-

jasthan. Maharashtra leads as the

largest selling state with almost 90

lakh packets sold in the region fol-

lowed by the South (75 lakh packets)

and North (45 lakh packets). The

northern market is mainly held by

Shriram Bioseeds.

A region wise split shows that the

Northern region of India recorded

maximum production of Bt cotton.

An important event of 2009 was

the approval of MLS 9124, developed

indigenously by Metahelix Life Sci-

ences. The product has a synthetic

cry 1C gene. The other development

was the release of two cotton hybrids

namely MH 5124 and MH 5174 ex-

pressing the synthetic cry 1C gene

(MLS 9124).

Notes: *Monsanto royalty has not beentaken into account as segment revenue

Agri biotech grew at 37% in FY 2009-10

There are over 30 companies marketing Bt cotton seeds in IndiaThe segment will grow at an average of 26% in the next 5 years

* BioSpectrum estimates


15/15

Biotech Directory

The BioIndustrial market

mainly comprising industrial

enzymes is estimated to be

Rs 564 crore in the year 2009-10 as

against Rs 478 crore in 2008-09. The

segment grew 16 percent in FY 2009-

10. Though the overall enzyme con-

sumption figures of India are com-

paratively low with respect to other

countries and 60-70 percent of domes-

tic demand is imported, the segment

on an average has been growing over

15 percent in the last five years.

In India, the industrial enzyme

consumption is predominantly in the

detergents market (40 percent), fol-

lowed by the starch market (25 per-

cent) . The other important segments

are food and feed, textiles, leather,

pulp and paper. In recent years, en-

zymes have found numerous appli-

cations in the food, pharmaceutical,diagnostic and chemical process-

ing industries. The trend for their

application in almost every sector

BioIndustrial to grow over 15% for next 5 years

BioIndustrial grew 16% in FY 2009-10

70% of the industrial enzyme domestic demand is imported

Top 3 BioInformatics Companies by Revenue (2009-10)Rank2010

Company 2009-10 (Revenuein Rs Cr)


% ChangeOver 2008-09

1 Ocimum Biosolutions 41.4 47.57 -12.97

2 Strand Life Sciences 35 35.00 0

is on increase.

The leading players in this segment

include Novozymes which has over 50

percent market share followed by Ad-

vanced Enzyme Technologies holding

25-30 percent market share. Other

important players are Maps, Gene-

cor, Lumis and Kerry Biosciences.

Besides, a new entrant Anthem Cel-

lutions, a part of Anthem Biosciences

group has gained significant market

share over a short period of time. Apart from focusing on the local

market, companies like Advanced

Enzyme Technologies are looking at

other markets such as China. Consid-

ering the potential opportunity in the

other markets Advanced Enzyme has

registered good growth in its export

sales.

The Indian companies are report-

ing a good growth, a lot of R&D is

happening in these companies and

new applications are being explored.

Indian companies are looking at

technologies from Europe, China and

Australia.However, with respect to global en-

zyme industry India still needs to do

a lot of catching up.

The smallest segment of the In-

dustry, BioInformatics which

has just about 2 percent seg-

ment share in the overall industry,

has been sluggish in FY 2009-10. It

registered a 5 percent growth over2008-09, clocking Rs 231 crore in rev-

enues last year as compared to Rs

220 crore in FY 2008-09, when it re-

corded a growth of 16 percent.

The pure-play BioInformatics compa-

nies in India include Strand Genom-

ics, Ocimum Biosolutions, SysArris,CytoGenomics and Molecular Connec-

BioInformatics grows at sluggish pace

Segment grows

at 5%Domestic marketcontributes 68% of

BioInformatics revenue

Segment Overview


Top 3 BioIndustrial Companies by Revenue (2009-10)Rank2010

Company 2009-10 (Revenuein Rs Cr)


% ChangeOver 2008-09

1 Novozymes SouthAsia*

268 250.00 7.2

2 Advanced Enzymes 121 88.60 36.57


*All figures in Rs. Crore unless indicated otherwise

tions. These companies have come out

with products that cater mainly to the

needs of the pharmaceutical and bio-

technology companies. Most of these

companies are small and medium en-

terprises based at locations such asBangalore, Hyderabad, Pune.

*BioSpectrum estimates

eighth bio spectrum june 10

Documents